anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed in the present invention are a composition containing lutein/lutein ester and applications thereof. Components of the composition containing lutein/lutein ester comprise lutein/lutein ester, β-carotene and a pharmaceutically acceptable carrier. The weight ratio of lutein/lutein ester to β-carotene is 1: 0.1-100. In the present invention, by cooperatively using lutein/lutein ester and β-carotene and using auxiliary natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through the oral cavity, has fast effectiveness and small first-pass effect, reduces damage of gastric acid to lutein/lutein ester, has high bioavailability, and has the characteristics of nutritional and health-care effects, good mouthfeel and fast absorption. By eating the product, visual power can be obviously enhanced, the ocular blood flow is increased, and eye muscle fatigue is alleviated, and accordingly the morbidities of cataract, senile niacula lutea retinae lesion and adolescent myopia are reduced.
Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
PURPOSE:To obtain a canine C-reactive protein (CRP) closely correlated to inflammatory diseases in a relatively good yield and in high purity, by separating and purifying the above-mentioned CRP using ion exchange chromatography, block electrophotoresis, etc., in combination. CONSTITUTION:Blood serum of a dog with acute inflammatory disease is first treated with, e.g. salt concentration elevation method for acute phase blood serum to give a fraction containing CRP, immunoglobulin, transferrin and ceruloplasmin. Stepwise elution is then carried out to afford a fraction consisting essentially of CRP, which is treated by affinity chromatography to adsorb and remove the immunoglobulin. The unadsorbed fraction is then treated by block separating electrophoresis to give the aimed mobile CRT having average 157,000 mol.wt. measured by a column gel filtration method and average 155,000mol.wt. measured by SDS-polyacrylamide gel electrophoresis and 4.75 isoelectric point at the slow-gamma position on the cathode side.
The first phase of study (Stage I) will use FI coregistered with pMR, iUS and iSV images to test the overall hypothesis that there is a high degree of spatial correlation between local tissue FI signal and coregistered conventional imaging and corresponding histopathology. Additionally, coregistered probe measurements and biopsy specimens will be acquired intraoperatively. Biopsy specimens will be processed post-operatively (via fluorescence microscopy and chemical spectrofluorimetry) to assess PpIX concentration which will allow direct comparisons of FI signal strength with PpIX production (based on both in vivo probe data and ex vivo histological quantification) as a function of histological grade. The study protocol is outlined below. Because of the overall interest and importance of relating this data to the existing body of literature and the excellent safety record of oral administration of ALA reported in these trials \[1, 33-36\], we will use the same dose/time schedule described in \[1, 33\]. The operative procedures will follow existing practice at Dartmouth for image-guided resection of meningiomas, pituitary adenomas and metastases with additional acquisition of FI and biopsy data at predefined time points that are related to the expected volume of tumor tissue. In this first phase of the study, resection decisions will not be made based on FI data alone. Should residual fluorescence remain after the intended resection volume has been removed further excisions will require biopsy confirmation in the OR. It is anticipated that 234 patients will be enrolled in Stage I.
Currently, malignant tumors are the leading cause of death. Surgery, chemotherapy, radiation therapy, and targeted therapy have become the four foundations of cancer treatment for many years. With the development of science and technology, immunotherapy has become the "fifth pillar" of cancer treatment. The most hot topic in immunotherapy is CAR-T therapy. The basic principle of CAR-T therapy (chimeric antigen receptor-T cells) is mainly to use the patient's own immune cells to clear cancer cells. CAR is a core component of CAR-T, conferring T cell a HLA-independent way to recognize tumor antigens, allowing CAR-modified T cells to recognize a broader target than the natural T cell surface receptor TCR. The basic design of CAR includes a tumor associated antigen (TAA) binding region, an extracellular hinge region, a transmembrane region and an intracellular signaling region. The selection of target antigens is a key determinant of the specificity and effectiveness of CAR and the safety of genetically modified T cells themselves.

Nectin-4 is a type I transmembrane protein whose extracellular domain is composed of three Ig-like domains (V-C-C type), which together with cadherin participate in the formation and maintenance of adhesion junctions. Nectin-4 is ubiquitously expressed in human embryonic cells but is hardly expressed in normal adult tissues. Nectin-4 is highly expressed on the surface of breast cancer, bladder cancer, non-small cell lung cancer, and pancreatic cancer cells, and plays a key role in the occurrence, invasion and metastasis of these epithelial malignancies. In conclusion, Nectin-4 is one of the important targets for the diagnosis and treatment of many solid tumors. The antibody-conjugated drug Enfortumab Vedotin targeting Nectin-4 was highly effective in Phase I clinical trials in 81 advanced bladder cancers, and was awarded FDA breakthrough therapy in March 2018. Fibroblast activation protein (FAP) belongs to the serine protease family and is highly expressed on the surface of cancer-associat
PURPOSE:To obtain the solid preparation having dissolving and eluting properties nearly equal to those of a liquid preparation, small in the size of the produced preparation, because the amount of the used base material is small, a little in the dosage of the preparation, and capable of being easily administered. CONSTITUTION:The solid solution-like solid composition comprises (A) etoposide and (B) a base agent selected from a water-soluble cellulose ether, polyvinyl pyrrolidone and their mixture, the amount of the component B being 2-4 pts.wt., preferably 2-3 pts.wt., per one pt.wt. of the component A. The water-soluble cellulose ether includes hydroxypropyl cellulose, especially the compound wherein the contents of the methyl group and the hydroxypropoxyl group are 19.0-30.0% and 4.0-12.0%, respectively. The polyvinyl pyrrolidone has a mol.wt. of 25000-1200000, especially approximately 40000. The composition is obtained by dissolving both the components in an organic solvent, and subsequently distilling off the organic solvent or spraying the solution on nuclear particles, etc.
A multi-component composition suitable for amalgamation with mercury to form a dental amalgam, an amalgam and a method for producing such a multi-component composition. The multi-component composition has: from 30 to 90% (by weight) of a first component containing at least 30% silver, at least 20% tin and at least 10% copper; from 10 to 70% (by weight) of a second component, or alternatively, from 5 to 65% (by weight) of a second component and from 5 to 65% (by weight) of a fourth component, the second and fourth components containing at least 30% silver, at least 20% tin and at least 10% copper; and up to 15% (by weight) of a third component containing silver and/or alloy powder containing at least 80% (by weight) silver. The first component is spherically shaped atomized alloy powder. The second component is mechanically worked atomized alloy powder. The surface area to volume ratio of the powder of the second component is greater than the surface area to volume ratio of the powder of the first component. The fourth component is irregularly shaped as atomized alloy powder.
NEW MATERIAL:The hydroxybiphenyl compound of formula I (R1 is H or OH; R2 is H or OH; R3 is OH, -CH2-CH=CH2 or -CH=CH-CHO; R4 is H or group of formula II; R5 is OH or group of formula III). USE:Useful as a drug or its intermediate, especially as an antiallergic agent. PROCESS:For example, TOKOBOKU (dried bark of Magnolia officinalis Rehd. et Wils. belonging to Magnoliaceae family) is extracted with water or methanol at room temperature and concentrated. The obtained extract is fractionated with water and ethyl acetate, and the ethyl acetate layer is concentrated. The obtained concentrate is subjected to chromatography with silica gel, and eluted with various solvents containing hexane, benzene, acetone and ethyl acetate at various ratios. The fraction eluted with ethyl acetate is subjected to column chromatography using silica gel, alumina, etc., and developed and eluted with a mixed solvent to obtain the objective compound of formula I .
Disclosed is a toothpaste composition comprising ultra low viscosity guar and carrageenan as a combination viscosity builder. In preferred embodiments of the toothpaste composition the combination viscosity builder comprises less than about 10% of the toothpaste composition by weight, and more preferably, about 0.5% to about 5% of the toothpaste composition by weight. The low viscosity guar preferably comprises less than about 50% of the combination viscosity builder by weight, and more preferably, about 20% to about 30% of the combination viscosity builder by weight. Also disclosed is a dry blend comprising about 20-30% low viscosity guar, about 50-60% iota-type carrageenan and about 20-30% lambda-type carrageenan. The specifications which relate to these components of the dry blend are identical to those discussed above in connection with the toothpaste composition. The dry blend, when appropriately hydrated, has a water viscosity of at least about 40 cps.
Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods. Contraceptive methods are discussed within this context. There will be no demand on participants to attend these sessions. Participants will receive written take-home materials to review on their own and/or with their sex partners.
The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient. The present invention also provides for a method of treatment of cancer, wherein such method involves the use of a therapeutic agent that stabilizes or reduces the amount of cancer stem cells in or from a patient.
Patients receive TLR9 agonist SD-101 intratumorally on days 1 and 8 of cycle 1 and day 1 of cycles 2-5. Treatment repeats every 2 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy on days 1, 3, 5, 8, and 10 of cycle 1. Patients also receive nivolumab IV over 30 minutes on day 2. Cycles with nivolumab repeat every 2 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
Eligible participants were randomized in two cohorts to receive COVID-HIG by IM, SC or IV in a 1:1:1 ratio and were stratified based on baseline SARS-CoV-2 IgG antibody status (low seropositive/seronegative; high seropositives were excluded). Up to 36 participants were planned to be enrolled and dosed in the study. A protocol amendment truncated the study to 23 randomized participants due to the impact of high circulating SARS-CoV-2 omicron cases on enrollment and participant retention. Participants were planned to be followed through Day 85 (approximately three half-lives), but the protocol was amended to shorten the study length to Day 57 due to timeline and PK considerations. The third substantial protocol amendment change was to remove the planned pseudovirus neutralization assay from the study due to its low sensitivity, limiting the PK analysis to the S-protein binding IgG immunoassay. PK time points included predose and postdose (from end of infusion/injection) 1 hr, 2 hr, 4 hr, 8 hr, 12 hr, Days 2, 3, 4, 6, 8, 15, 29, 43 and 57.

Nasopharyngeal swabs for SARS-CoV-2 were collected throughout the study. Per protocol, participants who became SARS-CoV-2 positive could not be assessed for PK at time points after testing positive, as the assay could not distinguish COVID-HIG from native antibodies. Participants who became SARS-CoV-2 positive during the study had disease severity assessed using an Ordinal Outcome Scale and followed via telemedicine through the end of the study.
The system has a training, seizing and radio requestable sensing unit (3) assigned to a training apparatus (2) to detect movements of the training apparatus during exercises and/or exercise movements. A mobile computer unit i.e. smartphone (1), is attached to a radio data connection unit that is attached to the sensing unit, pre-setting components (4) and/or payment systems, closure unit, detection facilities. The mobile computing unit analyzes and displays transmitted data of the sensor unit. An acceleration sensor is connected with a read-write memory. An independent claim is also included for a method for operating a system for processing mobile data and setting a training equipment in a gym and a medical rehabitation.
PURPOSE: A dispersible tablet composition containing olanzapine is provided to have hardness that is easy to handle and to produce a large amount of tablet. CONSTITUTION: A dispersible tablet contains 5-20 weight% of olanzapine or pharmaceutically acceptable salt, 1-20 weight% of disintegrant, 1-20 weight% of acid, 40-75 weight% of excipient, 0.01-5 weight% of sweetener, and 1-5 weight% of lubricant. The disintegrant is cross-linked polyvinyl pyrrolidone, corn starch, sodium starch glyconate, low substituted hydroxypropyl cellulose, or cross-linked sodium carboxyl methyl cellulose. The acid is citric acid, and excipient is micro crystalline cellulose, anhydrous dibasic calcium phosphate, xylitol, mannitol, or mixture thereof. The sweetener is sucralose and lubricant is sodium stearyl fumarate. The composition further contains a binder, surfactant, or mixture thereof.
These patients will have been randomized (via the parent trial, CREST-2) to receive medical management only, which includes aspirin. high dose cholesterol lowering agent to a target LDL\<70, intensive blood pressure management to target \<130/80, smoking cessation, and diabetic control.
The clinical heterogeneity of asthma patients has been increasingly recognised within the last years. Recent studies and articles highlighted the idea of asthma not beeing a single disease but rather a unifying term for multiple phenotypes. Phenotype in this sense is defined as the combination of observable properties of an organism, that are produced by the interactions of a genotype and the environment. In contrast, endotype describes a specific underlying pathophysiological pathway. Linking asthma phenotypes and endotypes in a system biological approach is an important research goal in order to develop targeted therapy, especially for severe asthma.

The advantage the investigators' cohort provides is the collaboration with an equivalent pediatric cohort. In this setting questions regarding disease onset, exacerbation and chronicity can be posed and worked with in a comprehensive manner.
The invention discloses a disease diagnosis prediction system based on a graph neural network, which comprises a knowledge map construction module, a data extraction and preprocessing module, a disease diagnosis model construction module and a disease diagnosis model application module. The invention effectively integrates expert knowledge and electronic medical record data in the knowledge map and constructs the heteromorphic graph network. On the heteromorphic graph network, local information and global information of the heteromorphic graph network are learned by utilizing a graph convolution neural network method. The disease diagnosis model can train the knowledge and data end to end simultaneously. In the model optimization target, besides the disease prediction task, supervision information on the knowledge relationship is added, so that the disease prediction task can effectively utilize knowledge, and the knowledge representation is not influenced by data noise. Aiming at the problems that the number of predicted diseases is large and the number of patients corresponding to part of the diseases is limited, multi-label hierarchical classification is designed for improving the prediction effect of few-sample class diseases.
There is a high incidence of sleep disturbances globally, especially among pregnant women. Long-term sleep disorders seriously affect the quality life of individuals, and it becomes undoubtedly an important public health problem. Studies have shown that sleep disorders during pregnancy can have short-term and long-term adverse effects on both mothers and their babies. In addition, sleep during pregnancy exhibits different characteristics at different stages. Most of the existing studies are based on the overall development trend to study sleep characteristics, ignoring potential individual differences. Based on the concept of precision medicine, this study intends to establish a cohort focusing on the sleep health of pregnant women, and carry out continuous home sleep monitoring of pregnant women from both subjective and objective perspectives. The aim of this study is, firstly, to explore the longitudinal change characteristics, potential classification and influencing factors of sleep during pregnancy; secondly, to analyze the differences in maternal and infant adverse outcomes among pregnant women with different sleep development trajectories. The final goal is to reveal the exposure window of maternal and infant adverse outcomes caused by sleep, thus improving the accuracy of outcome prediction, and promoting the development of accurate and personalized sleep management programs.
PCT No. PCT/US92/00063 Sec. 371 Date Sep. 11, 1992 Sec. 102(e) Date Sep. 11, 1992 PCT Filed Jan. 10, 1992 PCT Pub. No. WO92/11864 PCT Pub. Date Jul. 23, 1992A method is provided for qualitatively detecting in vitro the presence or absence of selected circulating antibody types using a diagnostic kit comprising reconstituted, after lyophilization or evaporative drying, red blood cell samples or other cell or cell-like material which have antigens which are recognized and bound by the selected antibody-type to be screened. Diagnostic kits containing the lyophilized blood samples according to the present invention have improved shelf life, and may comprise lyophilized samples packaged in a variety of forms convenient for manual single-test uses or automated multiple-test uses.
Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant.
Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
At international level, the WHO formulated guidelines for the treatment of severe acute malnutrition (or wasting) (WHO 1999, and more recently ACF 2011), and guidelines for moderate acute malnutrition (or wasting) are in the process of formulation. In contrast, surprisingly little is known on preventive schemes for acute malnutrition. In Haiti, Ruel et al (2008) found that targeting nutrition interventions to prevent children from becoming malnourished might be more effective than curative treatment to reduce child wasting. In addition, recent preventive trials in humanitarian settings focused on the use of food-based strategies, especially ready-to-use food (Isanaka, 2009; Hendricks, 2010; Parikh, 2010; Imbad, 2011; Huybregts, 2012). However, it is well known that the causes of under-nutrition are numerous and also relate to inadequate health and care practices, lack of food diversification, food insecurity... Therefore, the MAM'Out research project aims at assessing a context-adapted preventive approach, which is likely to influence several underlying causes of under-nutrition and not based primarily on food supplementation. The objective is to provide an evidence base for this alternative approach, in order that proven intervention be taken into account for scale-up at policy-making levels.
INTRODUCTION: Allograft dysfunction within the first week posttransplant is an uncommon but known complication following liver transplantation. Seventh-Day Syndrome (7DS) is a rare complication of allograft dysfunction following liver transplantation characterized by the rapid clinical deterioration of a formerly well-functioning allograft within the first week posttransplant. The etiology of 7DS is unknown, and treatment options remain limited. While cases of graft survival have been reported, the risk of mortality remains exceedingly high without urgent retransplantation.
METHODS: Patient data was retrospectively analyzed and a literature review performed.
RESULTS: We present a unique case of split liver transplantation into two pediatric recipients in which one recipient developed rapidly progressive graft failure approximately 1 week postoperatively requiring urgent retransplantation while the other recipient had an unremarkable postoperative course. Upon clinical manifestation of progressive graft failure, the patient was treated with thymoglobulin, rituximab, intravenous immunoglobulin, and plasmapheresis. Despite this, the patient's clinical status continued to decline and she underwent retransplantation 11 days following her initial liver transplant.
CONCLUSION: Seventh-Day Syndrome is a rare complication following liver transplantation that is associated with a high risk of morbidity and mortality. Our case adds to the limited literature on 7DS in children and is the first to report a comparative posttransplant clinical course in two recipients who received split grafts from the same donor.